Search

Contact Us
EU
Chinese
Resource Library / A Multimodal-Ready ctDNA Methylation Platform for Sensitive Minimal Residual Disease Detection

poster

A Multimodal-Ready ctDNA Methylation Platform for Sensitive Minimal Residual Disease Detection

Detecting minimal residual disease (MRD) at extremely low levels remains a major challenge in cancer monitoring. In this AAPS 2026 poster, Frontage scientists introduce a tissue-free ctDNA methylation platform capable of detecting tumor fractions as low as 0.005%, highlighting its potential for sensitive MRD detection with reduced sequencing requirements.

Resources to Consider

Left arrow
Method Validation of Quantitation IL-17A in Human Serum using the Ultrasensitive Quanterix Simoa™ Platform
poster

Method Validation of Quantitation IL-17A in Human Serum using the...
Interleukin17A (IL-17A) is disulfide-linked homo dimeric cytokine of 155 amino acids and a...
Access Resource
AAIC 2025: Comparison of Plasma pTau217 Assays on Different Platforms
poster

AAIC 2025: Comparison of Plasma pTau217 Assays on Different Platforms
Plasma pTau217 was recently discovered as a prominent blood-based biomarker in the early d...
Access Resource
Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using the Simoa HD-X platform
poster

Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using...
Alzheimer’s disease (AD) is a neurodegenerative disorder which stands as one of the most...
Access Resource
Testing of Carryover & After MRD Benchtop Stability for Pharmacokinetic Method Validation in Gyrolab Immunoassay Platform
white-paper

Testing of Carryover & After MRD Benchtop Stability for...
In this white paper, we show testing of two critical parameters for the method validation ...
Access Resource
Rapid, accurate and highly customizable assay platforms for pharmacogenomic studies
webinar

Rapid, accurate and highly customizable assay platforms for...
The diagnosis and treatment of human diseases and the development of new drugs increasingl...
Access Resource
Neurofilament Light Chain: Method Validation of Quantitation Using the Quanterix Simoa™ Platform and Potential Applications
poster

Neurofilament Light Chain: Method Validation of Quantitation Using...
In this study, we quantify Neurofilament Light Chain (NF-L) in human plasma, serum, and CS...
Access Resource
ADC PK Profiling Strategies on LC-MS Platforms: Top-down, Bottom-up, and Multiplexing
poster

ADC PK Profiling Strategies on LC-MS Platforms: Top-down, Bottom-up,...
With more monoclonal antibody (mAb) drug conjugates (ADC’s) under preclinical developmen...
Access Resource
WRIB 2025: Validation of an Ultra-High Sensitive Simoa Assay for the Quantitation of IL-17A in Human Serum
Access Resource
Validation of Ultra-high Sensitive SIMOA Assays for the Quantitation of NF-L and GFAP
poster

Validation of Ultra-high Sensitive SIMOA Assays for the Quantitation...
In this poster, we validate ultra-high sensitive SIMOA assays for the successful quantitat...
Access Resource
An Ultrasensitive LC-APPI-MS/MS Method for Simultaneous Determination of Ciclesonide and Active Metabolite Desisobutyryl-Ciclesonide inHuman Serum and Its Application to a Clinical Study
journal

An Ultrasensitive LC-APPI-MS/MS Method for Simultaneous Determination...
An Ultrasensitive LC-APPI-MS/MS Method for Simultaneous Determination of Ciclesonide and A...
Access Resource
Development and Validation of an Ultra Sensitive LC-MS/MS Method for Quantitation of Midazolam in Human Plasma
poster

Development and Validation of an Ultra Sensitive LC-MS/MS Method for...
Midazolam is a widely used central nervous system depressant. It is used for the treatment...
Access Resource
Developing an ELISA for residual host cell proteins (HCPs)
podcast

Developing an ELISA for residual host cell proteins (HCPs)
In this podcast, we discuss tips for developing an ELISA for residual host cell proteins (...
Access Resource
Right arrow